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on the extent of penetration into the bladder 
wall: non‑muscle invasive bladder cancer 
(NMIBC) or muscle invasive bladder cancer 
(MIBC). NMIBC is categorized by frequent 
recurrence of tumours and the potential to 
progress to muscle invasive disease [2]. The 
likelihood of recurrence and progression is 
determined by the risk profile of the patients, 
which is dependent on the severity of their 
disease [3]: low (solitary, primary low‑grade 
Ta tumour), intermediate (multiple or recur‑
rent low‑grade tumours), and high risk (any 
T1 and/or G3 and/or carcinoma in situ).
Bladder cancer accounts for approximately 
4.4% and 2.2% of all cancer cases world‑
wide in men and woman, respectively [4]. 
INTRODUCTION
Bladder cancer is a disease in which the cells 
lining the urinary bladder lose the ability to 
regulate their growth. As a consequence the 
cells start dividing uncontrollably. This ab‑
normal growth results in a mass of cells that 
form a tumour. Symptoms of bladder cancer 
typically include gross haematuria and uri‑
nary tract symptoms [1]. Due to the highly 
recurrent nature of the disease, bladder can‑
cer patients undergo intensive and costly 
routine monitoring and treatment, which 
combined with long survival makes bladder 
cancer one of the most expensive cancers to 
treat [1]. Bladder cancer can be broadly cat‑
egorized into two main groups depending 
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ABSTRACT
OBJECTIVE: To estimate the incremental cost‑effectiveness of hexaminolevulinate (Hexvix®) + Blue Light (H+BL) cys‑
toscopy (compared to white light cystoscopy only) when used at initial transurethral resection of the bladder tumour 
(TURBT) for patients diagnosed with non‑muscle invasive bladder cancer (NMIBC) in Italy.
METHODS: A cost‑effectiveness model has been developed to estimate the incremental cost‑effectiveness of introduc‑
ing H+BL at initial TURBT for patients diagnosed with NMIBC in Italy. The model consists of two parts: 1) a short term 
decision tree which estimates the outcome of the initial diagnostic procedure, and 2) a Markov cohort model which is used 
to estimate long term outcomes through extrapolation based on data and assumptions about patient management, the natu‑
ral history of the disease and the empirical efficacy of H+BL in improving diagnosis detection and reducing recurrence. 
Cost‑effectiveness results are expressed as incremental costs per QALY gained. Univariate and probabilistic sensitivity 
analyses are conducted to test the robustness of the model to changes in inputs and assumptions.
RESULTS: Base case results suggest that Hexvix® is a dominant strategy when used in the resection of NMIBC. Hexvix® 
is expected to be associated with 0.070 incremental QALYs, with cost savings of € 435 per patient. Sensitivity analyses 
suggest that the cost of Hexvix® and the relative risk of recurrence in intermediate and low risk groups are key drivers in 
the model. Probabilistic analyses indicate that Hexvix® is expected to be cost‑effective in >99% of iterations, assuming a 
willingness to pay threshold of € 25,000 per QALY.
CONCLUSION: In conclusion, Hexvix® is expected to be a cost‑effective strategy when used in the resection of NMIBC 
in Italy.
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In Italy during 2006‑2009 urinary bladder 
cancer ranked 5th among the most frequently 
diagnosed cancers after colorectal, breast, 
prostate, and lung (10% of all cancers among 
males and 2.8% of all cancers among fe‑
males) [5,6]. Regarding mortality, bladder 
cancer represents 3.6% of all cancer deaths 
(4.9% among male and 1.8% among females) 
[5].
Cigarette smoking and occupational ex‑
posure to urothelial carcinogens (aromatic 
amines such as benzidine and beta‑naphthyl‑
amine) are the two most well‑established risk 
factors for bladder cancer. Compared with 
non‑smokers, cigarette smoking is associ‑
ated with a 2 to 4 fold risk increase and an 
estimated population attributable risk for to‑
bacco smoking of approximately 50% in both 
men and women [7].
The primary approach to the treatment of 
NMIBC in Italy is transurethral resection of 
the bladder tumour (TURBT) as indicated in 
the Italian Association of Medical Oncology 
(AIOM) guidelines [8]. During a diagnosis or 
patient follow up the physician passes a thin, 
rigid, tube‑like telescope called cytoscape 
into the bladder through the patient’s urethra 
and white light is used to help locate any ab‑
normal growths or tumours. If any unusual 
growths or tumours are located on the blad‑
der wall, the physician will resect by insert‑
ing a special wire loop through the cytoscope 
and passing an electric current down the wire 
loop. The electric current is used to cut or 
burn off the growth or tumour and border of 
healthy tissue around it. Immediately follow‑
ing the TURBT, patients may receive intra‑
vescical therapy with either chemotherapy 
(mitomycin C) or Bacillus Calmette‑Guerin 
(BCG) [3]. This therapy is aimed at destroy‑
ing any post‑TURBT floating tumour cells 
which could end up replanting in the bladder 
wall. Follow‑up after cystectomy includes 
clinical assessment and CT scanning.
Hexvix® (hexaminolevulinate) is an optical 
imaging agent designed to enhance detection 
and resection of bladder cancer by inducing 
selective accumulation of photoactive por‑
phyrins in neoplastic cells, which fluoresce 
red under blue light accumulation. It has been 
shown in clinical trials that when compared 
to white light cystoscopy (WLC), Hexvix® 
enhances detection of lesions [9‑11], further‑
more by improving the completeness of the 
lesion resection and the subsequent tumour 
staging, Hexvix® results in a reduced number 
of recurrences and a more accurate risk clas‑
sification [3].
Indeed, more carcinoma in situ (CIS) lesions 
were found by Hexvix® guided cystoscopy 
than by white light cystoscopy in 41.5% of 
patients [12], furthermore 32% of the patients 
with CIS and 16% of the patients with TaT1 
tumours were detected with Hexvix® + blue 
light cystoscopy (H+BLC) only [13].
Improved resection and tumour staging al‑
lows the urologist/surgeon to make a more 
appropriate treatment decision (follow up 
cystoscopies and choice of adjuvant therapy), 
leading to improved recurrence free survival 
as shown in Jocham and colleagues’ study 
[14] where 22% of patients received more 
appropriate treatment at the time of the study 
because of a more exact assessment of risk 
categories following H+BLC cystoscopy. 
Moreover, in patients with Ta/T1 lesions, 
H+BLC demonstrated a 16% relative reduc‑
tion of short term tumour recurrence, com‑
pared to WLC alone (p = 0.026) [13]. With 
H+BLC urologists optimize management 
and increase control of their patients’ blad‑
der cancer by improving time to recurrence 
in the long‑term, as shown in the Grossman 
and colleagues study [15] where median 
time to recurrence was 9.4 months in the 
WLC group and 16.4 months in the H+BLC 
group [15]. In an additional analysis of the 
4.5 year follow up data, 83 patients (31.8%) 
in the WLC group and 97 patients (38%) in 
the H+BLC group remained tumour free af‑
ter initial resection, respectively (p = 0.14). 
Finally, T2‑T4 bladder cancer occurred twice 
as much in the WLC group (16 cases, 6.1%) 
compared to the H+BLC group (8 cases, 
3.1%; p = 0.066) [15].
The objective of the present analysis is to es‑
timate the incremental cost‑effectiveness of 
Hexvix® + blue light cystoscopy (H+BLC) 
compared to white light cystoscopy (WLC) 
when used at initial TURBT in patients diag‑
nosed with NMIBC in Italy.
METHODS
A cost‑effectiveness model has been devel‑
oped to estimate the incremental cost‑effec‑
tiveness of H+BLC (compared to WLC only) 
when used at initial TURBT in patients diag‑
nosed with NMIBC in Italy. The analysis was 
conducted with the perspective of the Italian 
National Health Service and over a lifelong 
time horizon to capture the entire incremen‑
tal effect on costs and health outcomes over 
a patient’s life. Incremental effects associated 
with H+BLC are estimated by following and 
comparing two realities: one representing 
WLC which is the standard of care and one 
in which Hexvix® is featured in the initial 
NMIBC treatment pathway.
The model is split into two parts: a short term 
decision tree which estimates the outcome of 
the initial diagnostic procedure, and a Mar‑
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kov cohort model which is used to estimate 
long term outcomes through extrapolation 
based on data and assumptions about patient 
management (based on the Italian clinical 
setting), the natural history of the disease and 
the empirical efficacy of H+BLC in improv‑
ing diagnosis detection and reducing recur‑
rence (Figure 1).
Model structure
Decision tree for initial diagnosis
A cohort of 1000 patients who are present‑
ing with symptoms of bladder cancer (micro‑
scopic or gross haematuria or lower urinary 
tract symptoms) enter the model at base‑
line. A certain percentage of these patients 
will have NMIBC. Muscle invasive bladder 
cancer (MIBC) patients are not considered 
at the start of the model. However, patients 
may progress to MIBC in the extrapolation 
period, in line with the natural progression of 
the disease.
The initial diagnosis is presented as a deci‑
sion tree (Figure 2); patients enter the deci‑
sion tree with symptoms of bladder can‑
cer and then receive an initial test/patient 
work‑up, which takes place in an outpatient 
setting. The exact nature of this initial test 
is not specified explicitly in the model as it 
does not create any incremental difference. It 
may consist of a mixture of flexible cystos‑
copy, cytology and/or biomarkers and may 
vary by country. This initial test is defined 
by a sensitivity and specificity, which when 
combined with a prevalence rate of NMIBC, 
determines the likelihood of a true positive, 
false positive, true negative or false negative 
test result.
It is assumed that all patients who test posi‑
tive in the initial test will be taken forward to 
the operating room (OR) for a TURBT, either 
by H+BLC (intervention arm) or WLC only 
(standard of care arm).
Although it is acknowledged that this diag‑
nosis process from start to finish may take 
Figure 1. Aggregate model structure
BC = bladder cancer
Figure 2. Structure of the decision tree for the initial diagnosis
weeks, or even months, the decision tree has 
no concept of time and instead represents a 
static ‘snapshot’ of the expected outcome 
distribution of a cohort of patients moving 
through such a diagnostic pathway. Each out‑
come of the decision tree is linked to a health 
state in the Markov model to establish start‑
ing health state distributions for the extrapo‑
lation period.
False positive patients incur the cost of the 
initial test and the cost of a TURBT (with a 
proportion getting mitomycin). It is then as‑
sumed that their status as false positives will 
be established at the post‑TURBT biopsy, 
and they will also be discharged. False posi‑
tive and true negative patients are moved to a 
cancer free state for the start of the extrapola‑
tion.
True positive patients incur the cost of an 
initial test and a TURBT (with a proportion 
getting mitomycin). Based on what was dis‑
covered during the initial TURBT, true posi‑
tive patients are stratified into one of three 
risk groups – defined by the stage and grade 
of the tumours present in their bladder. The 
following definitions of risk group are used, 
according to the European Organisation for 
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the frequency of follow‑up in bladder cancer 
patients in all risk groups.
In total, the extrapolation phase of the model 
consists of 21 health states which are reflec‑
tive of the status any given patient may have 
at any given time in the model and are defined 
by a patient’s risk group, and the outcome 
of the initial diagnosis, or the outcome of a 
patient’s most recent follow‑up: no tumour 
(true negative), false positive, recurrence 
(true positive), false negative (false negative 
at follow‑up) and missed patient (a false neg‑
ative at primary diagnosis). Note that there 
is no recurrence state for low risk patients, 
this is because low risk patients who have a 
recurrence are subsequently considered to be 
intermediate risk patients [3].
The health states are further differentiated ac‑
cording to whether or not a patient is pre‑re‑
currence or post‑recurrence. There is no 
evidence to suggest that any residual benefit 
from an initial H+BLC resection should per‑
sist beyond a subsequent resection by WLC 
due to a recurrence. Therefore, patients are 
only able to experience the benefit of Hexvix® 
up until their first recurrence. Post‑recurrent 
patients will face the same recurrence risk as 
WLC patients, to reflect that their most recent 
resection was conducted under WLC. There 
are also two states representing patients who 
have progressed to MIBC, locally muscle 
invasive (LMI) and metastases, as well as a 
state for patients who are cancer free (true 
negative and false positive patients at initial 
diagnosis). An absorbing state for patients 
who are dead (from cancer, treatment, proce‑
dure or otherwise) is also considered.
The frequency of patient follow‑up is depen‑
dent on risk group. The following frequen‑
cies are based on the EUA guidelines [3], and 
have been validated by an Italian clinical ex‑
pert [16]:
 ‑ low risk patients are followed up at 3 
months, 9 months and then annually 
thereafter;
 ‑ intermediate patients are followed up at 3 
months, 9 months and then bi‑annually;
 ‑ high risk patients are followed up at 3 
months, then every 3 months thereafter.
The health states in the Markov model are 
linked to the outcomes of the decision tree 
to establish starting distributions (Figure 3).
For NMIBC patients, follow‑up visits in‑
volve a similar diagnostic procedure as the 
initial diagnostic pathway. Instead of an un‑
specified initial test, patients will be first ex‑
amined with a flexible cystoscopy, followed 
by a TURBT if required. The base case model 
will only include H+BLC at the primary di‑
agnosis, therefore all follow‑up TURBTs will 
be assisted by WLC. True negative or false 
Figure 3. Link between decision tree primary diagnosis and the Markov health states
Research and Treatment of Cancer (EORTC) 
risk tables [9]:
 ‑ low‑risk: solitary, primary low‑grade 
TaG1/G2 tumour;
 ‑ intermediate risk: multiple or recurrent 
low‑grade TaG1/G2 tumours;
 ‑ high risk: any T1 and/or TaG3 and/or car‑
cinoma in situ.
In line with the European Urology Associa‑
tion (EUA) guidelines [3] and usual patient 
management in Italy [16], high risk patients 
will receive an early TURBT at 6 weeks, fol‑
lowed by BCG treatment, which consists of 
an induction course of weekly injections over 
a 6 week period, followed by instillations of 
weekly injections over 3 weeks at 3 months, 
6 months, 12 months, 18 months, 24 months 
and 30 months.
The extrapolation period of the model uses 
a patient’s risk group to determine their 
chance of both recurrence and progression, 
as well as their frequency of follow‑up and 
post‑TURBT management.
Patients who receive a false negative diag‑
nosis become ‘missed’ patients, as they have 
been discharged despite having cancer. These 
patients are followed and assumed to re‑enter 
the model at a later stage (for example when 
their symptoms worsen or no other cause for 
their symptoms is found). While untreated, it 
is assumed that these patients have a higher 
relative risk of progression to reflect the fact 
that they have cancer which has not been ap‑
propriately remedied.
Markov model
The second stage of the model is a Markov 
cohort model, which captures the prognosis 
of patients following their initial diagnostic 
procedure. In the base case, the model fol‑
lows all patients who received a TURBT 
(true positive and false positive patients). 
The structure of the model reflects the cur‑
rent guidelines for NMIBC patient follow‑up 
[3], and is based on real‑life evidence of 
bladder cancer evolution in terms of recur‑
rence and progression as observed from ob‑
servational studies; with inputs adapted to 
reflect Italian clinical practice with regards 
to patient management, from initial resection 
to follow up and monitoring for recurrence 
and progression (for details see the paragraph 
Model Parameters). The model time horizon 
is adjustable, but set to lifetime for the base 
case to capture the entire incremental effect 
on costs and QALYs over a patient’s life. The 
starting age of the cohort is 67, in line with 
a systematic literature review conducted to 
inform a previously published HTA [1]. The 
cycle length of the model is set to 3 months, 
which has been chosen to adequately capture 
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4). These transitions are given further granu‑
larity according to the outcome of patient 
follow‑up. If the patient has a follow‑up visit 
during a cycle, it may result in recurrence 
(true positive), no tumour recurrence (true 
negative), false positive, false negative, pro‑
gression or death. The risk group split reflects 
each patient’s probability to recur, progress 
and die, as well as move to a higher risk 
group.
Model parameters
Prevalence of bladder cancer
The prevalence of bladder cancer in the 
symptomatic population is not available from 
the literature. Based on estimates provided by 
expert opinion, it is assumed that 20% of pa‑
tients who present with bladder cancer symp‑
toms are indeed true positive patients [16].
Technology performance
The performance of flexible cystoscopy and 
of WLC has been taken from a UK‑based 
Figure 4. Health states transitions
negative patients will incur the cost of flex‑
ible cystoscopy only, and will be discharged 
until their next follow‑up visit.
Management of true positive or false positive 
patients depends on the patient’s risk group 
[16]:
 ‑ low risk patients will incur the cost of a 
TURBT, and will receive one instillation 
of mitomycin, and move to intermediate 
risk in the event of recurrence;
 ‑ intermediate risk patients incur the cost 
of a TURBT, and will receive one instil‑
lation of mitomycin. These patients also 
have a chance of being re‑evaluated as 
being high risk;
 ‑ high risk patients will incur the cost of a 
TURBT, and will receive one instillation 
of mitomycin. Patients will receive BCG 
therapy with re‑TURBT.
Patients who have progressed to MIBC are 
assumed to receive a TURBT, a computer‑
ized tomography (CT) scan and either cys‑
tectomy if LMI or cystectomy and palliative 
care if metastatic [16]. These patient man‑
agement pathways are in alignment with the 
EAU guidelines [3] and have been validated 
by an Italian expert [16].
Throughout the extrapolation phase of the 
model, patients may move between health 
states according to how their disease recurs 
or progresses, and the outcomes of their 
follow‑up visits. In any particular cycle, 
NMIBC patients may stay in their no tumour 
state, recur, progress to MIBC or die. Local 
MIBC patients may stay in their state, prog‑
ress to metastases, or die. Metastatic patients 
may either stay in their state or die (Figure 
the frequency of follow‑up in bladder cancer 
patients in all risk groups.
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by a patient’s risk group, and the outcome 
of the initial diagnosis, or the outcome of a 
patient’s most recent follow‑up: no tumour 
(true negative), false positive, recurrence 
(true positive), false negative (false negative 
at follow‑up) and missed patient (a false neg‑
ative at primary diagnosis). Note that there 
is no recurrence state for low risk patients, 
this is because low risk patients who have a 
recurrence are subsequently considered to be 
intermediate risk patients [3].
The health states are further differentiated ac‑
cording to whether or not a patient is pre‑re‑
currence or post‑recurrence. There is no 
evidence to suggest that any residual benefit 
from an initial H+BLC resection should per‑
sist beyond a subsequent resection by WLC 
due to a recurrence. Therefore, patients are 
only able to experience the benefit of Hexvix® 
up until their first recurrence. Post‑recurrent 
patients will face the same recurrence risk as 
WLC patients, to reflect that their most recent 
resection was conducted under WLC. There 
are also two states representing patients who 
have progressed to MIBC, locally muscle 
invasive (LMI) and metastases, as well as a 
state for patients who are cancer free (true 
negative and false positive patients at initial 
diagnosis). An absorbing state for patients 
who are dead (from cancer, treatment, proce‑
dure or otherwise) is also considered.
The frequency of patient follow‑up is depen‑
dent on risk group. The following frequen‑
cies are based on the EUA guidelines [3], and 
have been validated by an Italian clinical ex‑
pert [16]:
 ‑ low risk patients are followed up at 3 
months, 9 months and then annually 
thereafter;
 ‑ intermediate patients are followed up at 3 
months, 9 months and then bi‑annually;
 ‑ high risk patients are followed up at 3 
months, then every 3 months thereafter.
The health states in the Markov model are 
linked to the outcomes of the decision tree 
to establish starting distributions (Figure 3).
For NMIBC patients, follow‑up visits in‑
volve a similar diagnostic procedure as the 
initial diagnostic pathway. Instead of an un‑
specified initial test, patients will be first ex‑
amined with a flexible cystoscopy, followed 
by a TURBT if required. The base case model 
will only include H+BLC at the primary di‑
agnosis, therefore all follow‑up TURBTs will 
be assisted by WLC. True negative or false 
Figure 3. Link between decision tree primary diagnosis and the Markov health states
© SEEd All rights reserved86 Farmeconomia. Health economics and therapeutic pathways 2014; 15(3)
Cost-effectiveness analysis of hexaminolevulinate (Hexvix®) guided cystoscopy in Non-Muscle Invasive Bladder Cancer patients in Italy
characteristics in the study (80% male, mean 
age of 66) compare well to the cohort consid‑
ered in the current model. Data was available 
for 10 years of follow‑up. To allow popula‑
tion of the remaining model time horizon, it 
was assumed that the recurrence, progression 
and mortality rates are the same as the last 5 
years of this 10 year data.
Mortality rates associated with metastatic 
disease have been estimated based on a study 
by von der Maase and colleagues [19]. The 
study investigated the long‑term survival of 
metastatic bladder cancer patients in Den‑
mark. The follow‑up in the study was 5 years, 
beyond this time frame the mortality rate of 
metastatic cancer is assumed the same as be‑
tween year 3 and 5 of the 5 year data.
Relative risk of recurrence for H+BLC
Evidence suggests that H+BLC results in a 
‘better quality’ resection than WLC, result‑
ing in more cancer being removed, fewer 
residual cancer cells remaining and a subse‑
quently lower resulting probability of future 
recurrence [15]. This lower recurrence has 
been modelled using a relative risk of recur‑
rence for each of the three risk groups: 0.661, 
0.741, and 0.767 for low, intermediate, and 
high risk respectively [17].
Treatment
Based on clinical opinion, the following as‑
sumptions around concomitant treatment 
have been made [16]:
 ‑ 100% of patients receive mitomycin with 
their TURBT;
 ‑ 0% of recurrent intermediate risk patients 
will receive BCG therapy;
 ‑ 100% of high risk patients will receive 
BCG therapy.
Utilities and disutilities
Due to lack of evidence specific to NMIBC, 
it is assumed that the base utility value of 
patients in the model is in line with the UK 
EQ‑5D index score for a 67 year old patient 
[20]. This utility value (0.78) is applied to all 
NMIBC patients and to local MIBC patients. 
The utility value for metastases (0.436) and 
disutilities for various treatments (cystec‑
tomy: 0.17‑; TURBT: 0.1; BCG: 0.02) are 
derived from a cost‑utility analysis, with 6 
month cycles, conducted by Kulkarni and 
collegues [21].
Costs
The costs used in the analysis, alongside 
their sources, are shown in Table I (cost year 
2012). 
The cost of a CT scan, cystectomy, WL‑as‑
sisted TURBT, and the cost of mitomycin 
and BCG have been provided by Italian ex‑
perts [16]. The Healthcare Resource Groups 
Cost (€) Source
TURBT (WL) 2,350.00 Average of TURBT (WL) cost from two regions: Regione Lombardia and Regione Friuli venezia Giulia [16]
TURBT (BL) 2,882.40 Assumed to be cost of WL‑assisted TURBT plus the additional costs for Hexvix® (see Table II)
Flexible 
cystoscopy
540.98 UK National Health Service (NHS) reference costs 2011‑2012 [22]. Reference cost LB14E, day case 
converted to € using exchange rate 15/01/13 (1GBP = 1.20846 Euro)
CT scan 744.00 [16]
Cystectomy 10,600.00 Average of cystectomy cost from two regions: Regione Lombardia and Regione Friuli venezia Giulia [16]
Palliative 
care
17,764.36 UK NHS reference costs 2011‑2012 [22]. Assumed cost £392 per day for 37.5 days [16]. Reference 
cost SD01A, special palliative care: inpatient converted to € using exchange rate 15/01/13 
(1GBP = 1.20846 Euro)
Mitomycin C 66.00 Internal evaluation at Sant’Anna Hospital [16]
BCG 70.00 Internal evaluation at Sant’Anna Hospital [16]
Table I. Costs and their sources used in the model (cost year 2012)
model [1]. The estimates for WLC have been 
adjusted to estimate the sensitivity and speci‑
ficity of H+BLC based on the results from 
the meta‑analysis of Burger and colleagues 
[17]. This adjustment is based on the addi‑
tional detection that H+BLC exhibited over 
white light in patients with a solitary CIS. In 
the meta‑analysis, H+BLC detected 15.38% 
more solitary CIS (i.e. true positive patients 
vs. false negative patients) than WLC. The‑
refore, the sensitivity of H+BLC (relative to 
WL) has been inflated by 15.38%, resulting 
in a sensitivity of 0.82. This value is reached 
by estimating the relative detection with 
H+BLC versus WLC (60/52) and multiplying 
this with the sensitivity of WLC (71.0).
Risk distribution
Different risk stratifications for WLC and 
H+BLC are assumed due to the improved de‑
tection rates observed when using Hexvix®. 
For WLC it is assumed that 20% of patients 
are low risk, 50% are intermediate risk and 
30% are high risk [16]. For Hexvix® it is as‑
sumed that fewer patients will be in low risk, 
more patients in intermediate risk and similar 
proportions in high risk, based on the fin‑
dings from the meta‑analysis of Burger and 
colleagues (18.93%, 51.07% and 30.00%, re‑
spectively) [17].
General population mortality rates
General population mortality rates have 
been taken from Italian life tables [18]. Be‑
cause bladder cancer specific mortality rates 
are applied on top of the general population 
mortality rates, there may be some degree of 
double counting as population bladder cancer 
mortality will be captured to a small extent 
in the general population rates. The general 
population mortality estimates have been 
weighted to reflect the fact that approxima‑
tely 70% of bladder cancer patients are male.
Recurrence progression and 
cancer specific mortality rates
The recurrence, progression and mortality 
rates for NMIBC have been taken from a 
study by Millan‑Rodriguez and colleagues 
[10]. This was a retrospective cohort study of 
1,529 patients with primary NMIBC recor‑
ded in Spain in the years 1968‑96. The model 
follow‑up was only 5 years and so the recur‑
rence, progression and mortality rates for 
subsequent years in the current model were 
estimated from the mean data for the last 3 
years of the 5 year data. Recurrence, progres‑
sion and mortality rates for local MIBC have 
been taken from a retrospective cohort study 
from Canada [11], in which 1,054 patients 
with MIBC were treated with radical cystec‑
tomy between 1971 and 1997. The patient 
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 ‑ H+BLC is used at the resection stage in 
patients diagnosed with NMIBC;
 ‑ the starting age of the cohort is 67 years;
 ‑ the test at follow up is a flexible CSC;
 ‑ WLC is used for follow up TURBT’s, for 
both arms.
Sensitivity analyses
The cost‑effectiveness model has many pa‑
rameters that work interactively to provide 
the model outcomes. It is often unclear with‑
out further analyses which parameters have 
the most significant impact on the model out‑
comes, although the cost and efficacy of the 
intervention under consideration are usually 
key drivers in any economic model. Hence, 
sensitivity analyses are used to investigate 
how sensitive a model is to changes in input 
parameter values. Uncertainty margins are 
applied to each input parameter of interest 
based on corresponding margins provided in 
the literature or based on assumptions if in‑
formation is unavailable.
Univariate sensitivity analyses have been 
generated applying the assumption that the 
standard deviation is equal to 10% of the 
mean for all inputs. Lower and upper val‑
ues for parameters varied in the univariate 
sensitivity analyses are reported in Appen‑
dix A.
(HRGs) used to estimate the costs of pallia‑
tive care and flexible cystoscopy have been 
verified with UK and Italian experts and have 
been converted to Euros (1GBP = 1.20846 
Euros). The cost of Hexvix® is added to the 
cost of WL‑assisted TURBT to get the Hex‑
vix® assisted TURBT cost. The additional 
costs associated with using Hexvix® are 
shown in Table II.
Additional model assumptions
This model is based on real‑life evidence, a 
meta‑analysis of clinical evidence, Italian ex‑
pert opinion, and assumptions if information 
was not available.
An assumption of this model concerns the 
probability of cancer detection in missed 
patients that was taken from the aforemen‑
tioned published HTA [1] and has been 
validated with clinical experts (detection of 
missed patients: 25%, 50%, 75%, 100% for 
first 3 months, first year, end of second year, 
and end of third year, respectively), while 
the probability of moving from intermediate 
risk to high risk upon recurrence (0.133) was 
taken from the Kulkarni study [21]. Finally, 
if at any point a patient receives a false nega‑
tive diagnosis, it is assumed that there is a 
higher chance for them to progress relative to 
a patient with a true positive result, who has 
been appropriately treated. The relative risk 
of progression is set to 2.56. This value was 
derived from the additional progression in pa‑
tients who only received TURBT, compared 
to patients who received TURBT + BCG in 
the Millan‑Rodriguez study [10]. This value 
was also used in the UK HTA report [1] and 
in a cost impact model developed by the UK’s 
National Health System (NHS) [24].
Base case setting
The base case scenario evaluates (over a life‑
time horizon) the cost‑effectiveness of Hex‑
vix® guided cystoscopy when:
Cost (€) Source
Consumables 10.00 [16]
Additional 
equipment
522.40 PhotoDynamic Diagnosis (PDD) light source, 
light cable, dedicated camera, and dedicated 
optic [16,23]. The equipment costs for each 
procedure are based upon costs of Hexvix® 
at € 430 (2012) and these costs of equipment 
from the KARL STORZ Gmbh&Co. data [23]. It 
is assumed that the lifespan of the equipment 
is 5 years with 100 procedures each year
Table II. Additional costs for Hexvix®
characteristics in the study (80% male, mean 
age of 66) compare well to the cohort consid‑
ered in the current model. Data was available 
for 10 years of follow‑up. To allow popula‑
tion of the remaining model time horizon, it 
was assumed that the recurrence, progression 
and mortality rates are the same as the last 5 
years of this 10 year data.
Mortality rates associated with metastatic 
disease have been estimated based on a study 
by von der Maase and colleagues [19]. The 
study investigated the long‑term survival of 
metastatic bladder cancer patients in Den‑
mark. The follow‑up in the study was 5 years, 
beyond this time frame the mortality rate of 
metastatic cancer is assumed the same as be‑
tween year 3 and 5 of the 5 year data.
Relative risk of recurrence for H+BLC
Evidence suggests that H+BLC results in a 
‘better quality’ resection than WLC, result‑
ing in more cancer being removed, fewer 
residual cancer cells remaining and a subse‑
quently lower resulting probability of future 
recurrence [15]. This lower recurrence has 
been modelled using a relative risk of recur‑
rence for each of the three risk groups: 0.661, 
0.741, and 0.767 for low, intermediate, and 
high risk respectively [17].
Treatment
Based on clinical opinion, the following as‑
sumptions around concomitant treatment 
have been made [16]:
 ‑ 100% of patients receive mitomycin with 
their TURBT;
 ‑ 0% of recurrent intermediate risk patients 
will receive BCG therapy;
 ‑ 100% of high risk patients will receive 
BCG therapy.
Utilities and disutilities
Due to lack of evidence specific to NMIBC, 
it is assumed that the base utility value of 
patients in the model is in line with the UK 
EQ‑5D index score for a 67 year old patient 
[20]. This utility value (0.78) is applied to all 
NMIBC patients and to local MIBC patients. 
The utility value for metastases (0.436) and 
disutilities for various treatments (cystec‑
tomy: 0.17‑; TURBT: 0.1; BCG: 0.02) are 
derived from a cost‑utility analysis, with 6 
month cycles, conducted by Kulkarni and 
collegues [21].
Costs
The costs used in the analysis, alongside 
their sources, are shown in Table I (cost year 
2012). 
The cost of a CT scan, cystectomy, WL‑as‑
sisted TURBT, and the cost of mitomycin 
and BCG have been provided by Italian ex‑
perts [16]. The Healthcare Resource Groups 
Cost (€) Source
TURBT (WL) 2,350.00 Average of TURBT (WL) cost from two regions: Regione Lombardia and Regione Friuli venezia Giulia [16]
TURBT (BL) 2,882.40 Assumed to be cost of WL‑assisted TURBT plus the additional costs for Hexvix® (see Table II)
Flexible 
cystoscopy
540.98 UK National Health Service (NHS) reference costs 2011‑2012 [22]. Reference cost LB14E, day case 
converted to € using exchange rate 15/01/13 (1GBP = 1.20846 Euro)
CT scan 744.00 [16]
Cystectomy 10,600.00 Average of cystectomy cost from two regions: Regione Lombardia and Regione Friuli venezia Giulia [16]
Palliative 
care
17,764.36 UK NHS reference costs 2011‑2012 [22]. Assumed cost £392 per day for 37.5 days [16]. Reference 
cost SD01A, special palliative care: inpatient converted to € using exchange rate 15/01/13 
(1GBP = 1.20846 Euro)
Mitomycin C 66.00 Internal evaluation at Sant’Anna Hospital [16]
BCG 70.00 Internal evaluation at Sant’Anna Hospital [16]
Table I. Costs and their sources used in the model (cost year 2012)
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treated. The mean of the distribution was set 
as the point estimate in the model. Due to not 
having appropriate observations to estimate 
the standard deviation for each parameter, the 
standard deviation was assumed to be equal 
to 10% of the mean. Distributions applied in 
the probabilistic sensitivity analyses are re‑
ported in Appendix A.
Scenario analysis
In the base case analysis, patients who were 
initially misdiagnosed to be false negative 
are not taken into account, and are discharged 
at the initial diagnosis procedure. In terms of 
false negative patients, it is likely that they 
will return later onwards and will be treated 
with Hexvix®. This analysis assumes that 
these patients will at some point return for 
further diagnostics, due to persistent or wors‑
ening symptoms. A second analysis assumes 
a shorter model time horizon of 5 years.
RESULTS
Base case analysis
The base case analysis shows that when 
H+BLC is used at initial TURBT, it is con‑
sidered a dominant strategy when compared 
to WLC only. H+BLC is associated with cost 
savings related to additional patients diag‑
nosed, treated and followed‑up (‑€ 435), but 
also with better health outcomes (0.070 QA‑
LYs gained and 0.033 life years gained), as 
well as a reduction in the number of recur‑
rences, number of TURBTs and progression 
rates (Table III).
Sensitivity analysis
Univariate sensitivity analysis
Given the current inputs and assumptions in 
terms of the uncertainty surrounding these in‑
puts, the cost of Hexvix® is expected to have 
the largest impact on the ICER. This is shown 
by the widest bar at the top of Figure 5. This 
is expected because the cost of the interven‑
tion under investigation is often a key driver 
of results from economic models. Other key 
model drivers appear to include the relative 
risk of recurrence in low risk patients, the rel‑
ative risk of recurrence in intermediate risk 
patients and the cost of palliative treatment.
Probabilistic sensitivity analysis
The cost‑effectiveness acceptability curve 
demonstrates the probability that Hexvix® is 
cost‑effective at various willingness‑to‑pay 
thresholds, taking into account the uncer‑
tainty surrounding input parameters in a si‑
multaneous manner. Figure 6 illustrates that 
at a cost‑effectiveness threshold of 25,000 €/
H+BLC WLC Incremental
Life expectancy (years) 11.003 10.970 0.033
QALYs 8.06 7.99 0.070
Total costs (€) 28,086 28,521 ‑435
Recurrence (n.) 195 229 ‑34
TURBTs (n.) 365 399 ‑34
Progression to MIBC (n.) 24 25 ‑1
ICER (€) Dominant
Table III. Base case cost‑effectiveness results in when H+BLC is used at initial 
TURBT (life expectancy, QALYs, and total costs are per patient)
Figure 5. Univariate sensitivity analysis: impact of parameters change on ICER
corded. This constitutes one ‘simulation’. A 
thousand simulations are performed, which 
gives a distribution of ICERs, and conse‑
quently, an idea of the overall uncertainty 
surrounding the ICER estimate presented in 
the base case analysis. For the probability 
of events occurring (such as the probability 
of moving from intermediate to high risk), 
sensitivity and specificity, and utility values 
a beta distribution was applied. This is be‑
cause the beta distribution is restricted to the 
0‑1 space, in the same way as a probability 
is. A gamma distribution was fitted to costs 
and any resource use, as the gamma distribu‑
tion cannot fall below zero (but is otherwise 
unrestricted). A normal distribution was used 
to model the relative risk of progression if not 
A probabilistic sensitivity analyses was also 
conducted. Here, each parameter is varied 
simultaneously and the resulting ICER is re‑
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QALY, H+BLC is expected to be cost‑effec‑
tive in >99% of probabilistic iterations [25].
The cost‑effectiveness plane plots each itera‑
tion of the probabilistic sensitivity analysis in 
order to illustrate the variation in incremental 
costs and effects when parameters are varied 
simultaneously within their specified uncer‑
tainty boundaries.
Given the current inputs and the assump‑
tion that each input has an uncertainty mar‑
gin calculated based on a standard deviation 
equal to 10% of the mean, and assuming the 
distributions presented in Appendix, Figure 
7 demonstrates that H+BLC is expected to 
be cost‑saving in almost all cases (iterations 
are plotted on the bottom half of the figure). 
Figure 6. Cost‑effectiveness acceptability curve
Figure 7. Cost‑effectiveness plane. Note: no simulations produced negative 
incremental QALYs.
treated. The mean of the distribution was set 
as the point estimate in the model. Due to not 
having appropriate observations to estimate 
the standard deviation for each parameter, the 
standard deviation was assumed to be equal 
to 10% of the mean. Distributions applied in 
the probabilistic sensitivity analyses are re‑
ported in Appendix A.
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to WLC only. H+BLC is associated with cost 
savings related to additional patients diag‑
nosed, treated and followed‑up (‑€ 435), but 
also with better health outcomes (0.070 QA‑
LYs gained and 0.033 life years gained), as 
well as a reduction in the number of recur‑
rences, number of TURBTs and progression 
rates (Table III).
Sensitivity analysis
Univariate sensitivity analysis
Given the current inputs and assumptions in 
terms of the uncertainty surrounding these in‑
puts, the cost of Hexvix® is expected to have 
the largest impact on the ICER. This is shown 
by the widest bar at the top of Figure 5. This 
is expected because the cost of the interven‑
tion under investigation is often a key driver 
of results from economic models. Other key 
model drivers appear to include the relative 
risk of recurrence in low risk patients, the rel‑
ative risk of recurrence in intermediate risk 
patients and the cost of palliative treatment.
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The cost‑effectiveness acceptability curve 
demonstrates the probability that Hexvix® is 
cost‑effective at various willingness‑to‑pay 
thresholds, taking into account the uncer‑
tainty surrounding input parameters in a si‑
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at a cost‑effectiveness threshold of 25,000 €/
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Life expectancy (years) 11.003 10.970 0.033
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Figure 5. Univariate sensitivity analysis: impact of parameters change on ICER
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DISCUSSION
Bladder cancer is the fourth most common 
malignancy among men in the Western world 
(after prostate, lung, and colon cancers) [26] 
and accounts for approximately 5‑10% of all 
cancers in Europe and the United States [27]. 
The incidence of bladder cancer increases 
with age [27] and is up to 3‑fold more com‑
mon in men than in women [28].
The majority of bladder cancer (approxi‑
mately 75‑85%) are NMIBC which is charac‑
terized by its tendency to recur after resection 
and to progress to muscle invasive disease. 
Bladder cancer has the highest lifetime treat‑
ment costs per patient of all cancers from di‑
agnosis to death due in particular to the sub‑
sequent high recurrence rates and need for 
ongoing invasive monitoring requirements 
[29].
Treatment of NMIBC is based on transure‑
thral resection of the bladder (TURBTs) 
with post‑treatment bladder instillations of 
chemotherapy or immunotherapy (adjuvant 
treatment). Due to the tendency of NMIBC 
tumors to recur, TURBTs are often repeated. 
Therefore, TURBTs usually represent the 
largest costs in terms of treatment expendi‑
ture for bladder cancer patients. The quality 
and result of the initial TURBT strongly de‑
termines the patient’s prognosis and overall 
bladder cancer treatment costs. Better initial 
resection and staging could avoid additional 
TURBTs resulting in clinical, quality of life, 
and economic benefits.
The EAU guidelines recommend that if 
equipment is available, fluorescence‑guided 
biopsy should be performed when bladder 
CIS is suspected (e.g. positive cytology, re‑
current tumor with previous history of a 
high‑grade lesion) [3].
Hexvix® is an optical imaging agent designed 
to enhance detection of bladder cancer. Fur‑
thermore, H+BLC helps improve resection 
and leads to more accurate staging and fewer 
residual tumours in patients with NMIBC 
[12,13].
A European expert panel recommended that 
H+BLC be used in patients with positive 
urine cytology but negative WLC for the as‑
sessment of tumour recurrences in patients 
not previously assessed with Hexvix® [30]. 
The recommendations also postulated that 
the use of H+BLC is likely to be advanta‑
geous in the initial follow‑up of patients with 
CIS or multifocal tumours.
European economic studies have demonstrat‑
ed that costs of fluorescence cystoscopy can 
be reduced through savings from fewer trans‑
urethral resections of the bladder (TURBTs) 
in follow‑up. Sievert et al. [29] indicated that 
H+BLC WLC Incremental
Life expectancy (years) 4.333 4.331 0.001
QALYs 3.01 2.97 0.033
Total costs (€) 14,071 14,075 ‑4
Recurrence (n.) 92 115 ‑23
TURBTs (n.) 248 272 ‑24
Progression to MIBC (n.) 24 25 ‑1
ICER (€) Dominant
Table IV. Cost‑effectiveness results assuming a 5 year model time horizon 
(calculated on 1000 patients with suspected bladder cancer; life expectancy, 
QALYs, and total costs are per patient)
According to the current model inputs and 
estimates of uncertainty surrounding these, 
H+BLC will always result in additional QA‑
LYs versus WLC.
Scenario analysis
H+BLC used in positive 
and false negative patients
When used in positive and false negative 
patients H+BLC is a dominant strategy as 
compared to WLC only and it is associated 
with better patients’ health outcomes (0.014 
QALYs gained and 0.007 life years gained), 
a reduction in healthcare expenditures (€ 58 
decrease in total costs) and a lower risk of 
recurrence, TURBTs and progression (Table 
IV).
In this scenario the additional cost of Hex‑
vix® is the biggest driver of the ICER and the 
PSA suggests that H+BLC has a probability 
of being cost‑effective at a willingness to pay 
threshold of 25,000 €/QALY of >99%.
5 years model horizon
This analysis has demonstrated that H+BLC 
may still be considered a dominant strategy 
compared to WLC when analysed over a 5 
year time horizon (Table V). Hexvix® is ex‑
pected to be cost‑effective in >99% of PSA 
interactions in this scenario.
H+BLC WLC Incremental
Life expectancy (years) 12.034 12.027 0.007
QALYs 9.27 9.26 0.014
Total costs (€) 6,114 6,172 ‑58
Recurrence (n.) 256 302 ‑46
TURBTs (n.) 495 542 ‑47
Progression to MIBC (n.) 36 37 ‑1
ICER (€) Dominant
Table IV. Cost‑effectiveness results when Hexvix® is used in positive and false 
negative patients (calculated on 1000 patients with suspected bladder cancer; 
life expectancy, QALYs, and total costs are per patient) – lifelong timeframe
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demonstrating that the benefits of H+BLC 
in term of recurrence, TURBTs and progres‑
sions avoided are already evident over a short 
time‑frame.
A key strength of the model presented here 
is its flexibility to model various scenarios, 
including various assumed risk distributions 
and NMIBC population assumptions. The 
model has a lifetime horizon, thus captur‑
ing all potential benefits of Hexvix® use. In 
particular, the benefits of H+BLC in terms of 
the evidence showing its enhanced detection 
of lesions, and benefits in terms of complete 
resection are explicitly modelled.
A limitation of the model concerns the in‑
puts used for this Italian analysis. For some 
inputs, UK‑based cost estimates have been 
converted to Euros to estimate the Italian 
input. Whilst this is not ideal, the UK costs 
were checked by an Italian clinical expert 
who confirmed that they were representa‑
tive of expected costs in Italy. Furthermore, 
one‑way sensitivity analyses have demon‑
strated that these cost estimates are not key 
drivers of the model results.
The results of the model presented here are 
in line with previously developed models of 
NMIBC which have demonstrated promising 
results for PDD [1,2].
CONCLUSIONS
This cost‑effectiveness analysis demonstrates 
improved patients’ health outcomes, with less 
procedures and hospital visits, and savings in 
health care expenditures offsetting invest‑
ment in Hexvix® technology in the long‑term. 
Even over a shorter timeframe, H+BLC is as‑
sociated with lower overall costs compared 
to WLC.
From a public health perspective, this analy‑
sis shows that the use of H+BLC in the man‑
agement of NMIBC may lead to an enhanced 
use of clinical services with less hospitaliza‑
tion for MIBC and better support for patients. 
In conclusion, Hexvix® is expected to be a 
cost‑effective strategy when used in the re‑
section of NMIBC in Italy.
initial H+BLC costs can potentially be off‑
set by fewer TURBT follow‑ups. In a Swed‑
ish study, Malmstrom et al. [2] reported that 
the avoidance of TURBTs and cystectomies 
by using H+BLC instead of WLC would 
result in a saving of € 137,461 to the health 
service. Finally, a cost impact model devel‑
oped by the UK’s NHS Technology Adoption 
Centre (NTAC) [24] estimated that H+BLC 
with TURBT could save over 2100 bed days 
across the NHS over 5 years.
The cost‑effectiveness model presented here 
is based on Markov modeling techniques. The 
model was developed to assess the cost‑effec‑
tiveness of Hexvix® when used in the resec‑
tion of NMIBC over a lifelong time horizon 
in the Italian National Health Service.
Base case results suggest that Hexvix® is a 
dominant strategy when used in the resection 
of NMIBC. H+BLC is expected to be asso‑
ciated with 0.070 incremental QALYs, with 
cost savings of € 435 per patient. Hexvix® is 
also associated with a decrease in invasive 
procedures due to earlier diagnosis.
Sensitivity analyses suggest that the cost of 
H+BLC and the relative risk of recurrence 
in intermediate and low risk groups are key 
drivers in the model. Probabilistic analyses 
indicate that H+BLC is expected to be cost‑ef‑
fective in >99% of iterations, assuming a will‑
ingness to pay threshold of 25,000 €/QALY.
H+BLC is found to be dominant versus 
WLC when used in positive and false nega‑
tive patients. In this scenario, H+BLC is as‑
sociated with better patient outcomes and a 
reduction in healthcare expenditure offset‑
ting the investment for Hexvix® technology 
(€ 58 decrease in total costs; 0.014 QALYs 
gained). Furthermore, improvement in resec‑
tion completeness and tumor staging, and the 
subsequent lower risk of recurrence allow 
for more effective management of patients 
and decrease the number of recurrences and 
repeated procedures. This leads to better 
health outcomes for patients and offers some 
long‑run savings to the Italian NHS.
Finally, H+BLC is considered dominant 
when modeled over a 5 year time horizon, 
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APPENDIX
Variable Base Case Lower Limit Upper Limit
QALY discount rate 3.50%
Cost discount rate 3.50%
% of patients male 70.00% 55.47% 82.72%
Bladder cancer prevalence 20.00% 16.23% 24.06%
Sensitivity Flexible cystoscopy 0.95 0.65 1.00
Sensitivity White light cystoscopy 0.95
Specificity Flexible cystoscopy 0.72 0.57 0.85
Specificity White light cystoscopy 0.72
RR of progression for NMIBC (Tx vs. no Tx) 2.56 2.06 3.06
RR of recurrence H+BL (low risk) 0.66 0.53 0.78
RR of recurrence H+BL (intermediate risk) 0.74 0.58 0.87
RR of recurrence H+BL (high risk) 0.77 0.60 0.90
Probability of progression with metastases 0.25 0.20 0.30
Cost CSC per use € 541 € 259 € 924
Cost WLC assisted TURBT € 2,350 € 1,127 € 4,015
Cost of cystectomy € 10,600 € 5,083 € 18,110
Cost Palliative treatment (per 3 months) € 17,764 € 8,519 € 30,350
Cost CT scan € 744 € 357 € 1,271
Cost mitomycin dose (cost per 40mg vial) € 66 € 32 € 113
Cost BCG dose (cost per 12.5 mg vial) € 70 € 34 € 120
Additional cost of Hexvix® + BL € 532 € 255 € 910
Base bladder cancer utility (annual) 0.780 0.610 0.911
Utility metastases (annual) 0.436 0.352 0.522
Cystectomy disutility 0.340 0.275 0.408
CSC disutility 0.000 0.000 0.000
WLC disutility 0.000 0.000 0.000
W&BLC disutility 0.000 0.000 0.000
WLC assisted TURBT disutility 0.200 0.162 0.241
BCG disutility 0.040 0.033 0.048
Move to high risk from inter on recur 0.130 0.108 0.160
% mitomycin post‑initial TURBT 1.000 1.000 1.000
% BCG inter risk (post recur) 0.000 0.000 0.000
% BCG high risk 1.000 1.000 1.000
% of metastatic patients receiving cystectomy 1.000 1.000 1.000
Lower and upper values for parameters varied in the univariate sensitivity analyses
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Variable Base Case Distribution St. dev alpha beta
% of patients male 70.00 Beta 0.07 29.3 12.6
Bladder cancer prevalence 20.00% Beta 0.02 79.8 319.2
Sensitivity Flexible cystoscopy 0.95 Beta 0.095 4.05 0.2
Sensitivity White light cystoscopy 0.95 Beta
Specificity Flexible cystoscopy 0.72 Beta 0.07 27.3 10.6
Specificity White light cystoscopy 0.72
RR of progression for NMIBC (Tx vs no Tx) 2.56 Normal 0.256
RR of recurrence H+BL (low risk) 0.66 Beta 0.07 33.2 17.0
RR of recurrence H+BL (intermediate risk) 0.74 Beta 0.07 25.2 8.8
RR of recurrence H+BL (high risk) 0.77 Beta 0.08 22.5 6.8
Distribution WL (low risk) 0.20 Dirichlet 0.04 19.8 variable
Distribution WL (intermediate risk) 0.50 Dirichlet 0.05 49.5 variable
Distribution WL (high risk) 0.30 Dirichlet 0.05 29.7 variable
Difference in Distribution WL+BL (intermediate risk) 0.011 Beta 0.00107 98.9193 9145.875
Probability of progression with metastases 0.25 Beta 0.03 74.8 224.3
Cost CSC per use € 541 Gamma 54.1 10 54.1
Cost WLC assisted TURBT € 2,350 Gamma 235 10 235
Cost of cystectomy € 10,600 Gamma 1,060 10 1,060
Cost Palliative treatment (per 3 months) € 17,764 Gamma 1,777 10 1,777
Cost CT scan € 744 Gamma 74.4 10 74.4
Cost Mitomycin dose (cost per 40mg vial) € 66 Gamma 6.6 10 6.6
Cost BCG dose (cost per 12.5mg vial) € 70 Gamma 7 10 7
Additional cost of Hexvix® + BL € 532 Gamma 53.24 10 53.24
Base bladder cancer utility (annual) 0.780 Beta 0.08 21.2 6.0
Utility metastases (annual) 0.436 Beta 0.04 56.0 72.4
Cystectomy disutility 0.34 Beta 0.03 65.7 127.5
WLC assisted TURBT disutility 0.20 Beta 0.02 79.8 319.2
W&BLC assisted TURBT disutility 0.20 Beta 0.02 79.8 319.2
BCG disutility 0.04 Beta 0.00 96.0 2,303.0
Move to high risk from inter on recur 0.13 Beta 0.01 86.6 564.3
% mitomycin post‑initial TURBT 1.00 Beta 0.10 ‑1.0 0.0
% BCG high risk 1.00 Beta 0.10 ‑1.0 0.0
% of metastatic patients receiving cystectomy 1.00 Beta 0.10 ‑1.0 0.0
Distributions applied in the probabilistic sensitivity analyses
